Kintor Pharmaceutical Limited
HKEX:9939.HK
1.13 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | 2016 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.034 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 |
| Cost of Revenue
| 0.042 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.042 | 0 | 0 | 0 | 0.034 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0.001 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.312 | -1.221 | 0.857 | 0.716 |
| Reseach & Development Expenses
| 0.774 | 0.165 | 0.367 | 0.461 | 0.486 | 0.282 | 0.18 | 0.148 | 0.125 | 0.089 | 0.025 | 0.02 | 0.013 | 0.01 |
| General & Administrative Expenses
| 0.037 | 0.051 | 0.066 | 0.065 | 0.052 | 0.05 | 0.052 | 0.024 | 0.01 | 0.009 | 0.027 | 0.022 | 0.016 | 0.044 |
| Selling & Marketing Expenses
| 0.002 | 0.009 | 0.01 | 0.011 | 0.009 | 0.006 | 0.005 | 0.004 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 0.036 | 0.06 | 0.076 | 0.076 | 0.062 | 0.056 | 0.058 | 0.028 | 0.012 | 0.009 | 0.028 | 0.023 | 0.016 | 0.044 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 0.815 | 0.215 | 0.432 | 0.52 | 0.556 | 0.33 | 0.318 | 0.197 | 0.135 | 0.098 | 0.022 | 0.023 | 0.013 | 0.043 |
| Operating Income
| -0.853 | -0.216 | -0.435 | -0.534 | -0.502 | -0.333 | -0.226 | -0.174 | -0.123 | -0.096 | -0.024 | -0.023 | -0.016 | -0.043 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -14.662 | 0 | 0 | 0 | 0 | 0 | -48.891 | -2,638.628 | -51.388 | -37.456 |
| Total Other Income Expenses Net
| -0.003 | 0.004 | 0 | 0.015 | -0.014 | 0.007 | -0.087 | -0.021 | -0.012 | -0.003 | 0 | -0 | 0.003 | 0.001 |
| Income Before Tax
| -0.856 | -0.213 | -0.435 | -0.518 | -0.516 | -0.326 | -0.313 | -0.195 | -0.134 | -0.099 | -0.023 | -0.023 | -0.012 | -0.042 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -15.082 | 0 | 0 | 0 | 0 | 0 | -48.151 | -2,694.58 | -40.559 | -36.269 |
| Income Tax Expense
| 0.008 | 0.001 | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -0.849 | -0.212 | -0.436 | -0.518 | -0.516 | -0.326 | -0.313 | -0.195 | -0.134 | -0.099 | -0.023 | -0.023 | -0.012 | -0.042 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -15.082 | 0 | 0 | 0 | 0 | 0 | -48.21 | -2,692.129 | -40.601 | -36.269 |
| EPS
| -1.98 | -0.5 | -1.13 | -1.42 | -1.42 | -0.93 | -0.9 | -0.72 | -0.54 | -0.43 | -0.12 | -0.12 | -0.067 | -0.22 |
| EPS Diluted
| -1.98 | -0.5 | -1.13 | -1.42 | -1.42 | -0.93 | -0.9 | -0.72 | -0.54 | -0.43 | -0.12 | -0.12 | -0.067 | -0.22 |
| EBITDA
| -0.847 | -0.209 | -0.428 | -0.528 | -0.498 | -0.33 | -0.223 | -0.173 | -0.122 | -0.095 | -0.023 | -0.022 | -0.016 | -0.043 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -14.551 | 0 | 0 | 0 | 0 | 0 | -47.629 | -2,582.107 | -50.471 | -37.269 |